EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Evolution of liver disease severity and portal hypertension during REP 2139-Mg treatment in 3 patients with chronic hepatitis D

Mathias Jachs, Michael Schwarz, Mattias Mandorfer, Andrew Vaillant, Thomas Reiberger

Wiener klinische Wochenschrift · 2026-11 · 138 (21-22) · 697-700

DOI: 10.1007/s00508-026-02748-2 ↗
AbstractBibliografische Angaben

Abstract

Summary Treatment options for chronic hepatitis D (CHD) are limited in patients who do not respond to recommended treatment with bulevirtide ± pegylated interferon. The use of REP 2139-Mg is a novel treatment option that has recently demonstrated efficacy and safety in phase 2 trials and a compassionate access program that included three patients treated at the Vienna General Hospital with compensated advanced chronic liver disease and clinically significant portal hypertension (CSPH). Long-term outcome of CSPH patients treated with REP 2139-Mg is unknown; thus, surrogate endpoints are of interest in this population. In the 3 patients receiving REP 2139-Mg for 12 months at our center, we monitored the hepatic venous pressure gradient (HVPG) as the strongest prognostic surrogate biomarker in compensated cirrhosis at baseline, and after 3 and 12 months of treatment. The HVPG dynamics alongside additional liver function tests observed are summarized in this report and two out of three patients achieved undetectable hepatitis-D-virus(HDV)-RNA and low hepatitis B surface Antigen (HBsAg) following pronounced alanine aminotransferase (ALT) flares during REP 2139-Mg treatment. The first patient showed virologic non-response and no HVPG dynamics during treatment. The second patient developed jaundice upon treatment initiation, resulting in a transient increase in HVPG despite virologic response. The third patient achieved virologic response that was paralleled by sustained reductions in HVPG.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →